Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study

Bibliographic Details
Main Authors:	Hopewell, J, Parish, S, Armitage, J, Collins, R
Format:	Journal article
Published:	2011

Similar Items

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
by: Hopewell, J, et al.
Published: (2013)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
by: Hopewell, J, et al.
Published: (2009)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
by: Hopewell, J, et al.
Published: (2011)

Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study
by: Hopewell, J, et al.
Published: (2010)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
by: Hopewell, J, et al.
Published: (2011)

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
by: Parish, S, et al.
Published: (2012)

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
by: Hopewell, J, et al.
Published: (2011)

Heart Protection Study - Reply
by: Collins, R, et al.
Published: (2003)

C-reactive protein in the Heart Protection Study - Authors' reply
by: Emberson, J, et al.
Published: (2011)

Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE
by: Hopewell, J, et al.
Published: (2012)

New analyses of Heart Protection Study - Reply
by: Collins, R, et al.
Published: (2004)

MRC/BHF Heart Protection Study - Reply
by: Collins, R, et al.
Published: (2002)

C-reactive protein in the Heart Protection Study Reply
by: Emberson, J, et al.
Published: (2011)

Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
by: Hopewell, J, et al.
Published: (2014)

Cardiovascular outcomes among participants with diabetes in the recent large statin trials.
by: Armitage, J, et al.
Published: (2004)

Comments on the MRC/BHF Heart Protection Study - Authors' reply
by: Collins, R, et al.
Published: (2003)

Misrepresentation of statin safety evidence.
by: Armitage, J, et al.
Published: (2014)

Economic evaluation of the Heart Protection Study
by: Briggs, A, et al.
Published: (2003)

The Impact of Genetic Variants Related to LDL-cholesterol on Risk of Ischemic Stroke and Coronary Heart Disease
by: Hopewell, J, et al.
Published: (2012)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
by: Mangravite, L, et al.
Published: (2013)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
by: Mangravite, L, et al.
Published: (2013)

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
by: Collins, R, et al.
Published: (2003)

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
by: Mihaylova, B, et al.
Published: (2009)

Lessons from the controversy over statins - Authors' reply.
by: Armitage, J, et al.
Published: (2016)

NON-LIPID MECHANISMS OF STATINS ACTION FOR HEART TRANSPLANT RECIPIENTS
by: А. О. Shevchenko, et al.
Published: (2013-05-01)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
by: Emberson, J, et al.
Published: (2005)

The safety of statins in clinical practice.
by: Armitage, J
Published: (2007)

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
by: Link, E, et al.
Published: (2008)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
by: Collins, R, et al.
Published: (2002)

Safety and efficacy of statins - Authors' reply
by: Collins, R, et al.
Published: (2017)

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
by: Kearney, P, et al.
Published: (2008)

The MRC/BHF Heart Protection Study: preliminary results.
by: Collins, R, et al.
Published: (2002)

AGW 705 - ADVANCED MARKETING SEMINAR APRIL 08.
by: PPP, Pusat Pengajian Pengurusan
Published: (2008)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
by: Bulbulia, R, et al.
Published: (2007)

Benefits of reducing LDL cholesterol among 18,686 patients with diabetes: Meta-analysis of 14 radomized trials of a statin versus control
by: Kearney, P, et al.
Published: (2006)

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
by: Emberson, J, et al.
Published: (2005)

The genomic basis of mood instability: identification of 46 loci in 363,705 UK Biobank participants, genetic correlation with psychiatric disorders, and association with gene expression and function
by: Harrison, P, et al.
Published: (2019)

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
by: Reith, CA, et al.
Published: (2024)

Corrigendum to "Stress Perfusion Imaging Using Cardiovascular Magnetic Resonance: A Review" [Heart Lung Circ. 19 (2010) 697-705]
by: Christiansen, J, et al.
Published: (2011)

An Investigation into Turning of ASSAB-705 Steel Using Multiple Sensors
by: Bhuiyan, M.S.H., et al.
Published: (2016)